RXRX Earnings

RXRX reported its FY2025Q4 earnings on 2026-03-09, showcasing a revenue of against an estimate of 21.22M, resulting in a 0% surprise. The EPS was 0, surpassing the expected -0.28 by 0%. The stock experienced a 0% price change on the earnings day and a 0% change over the next five days, reflecting market reactions to the results.

Following RXRX's FY2025Q4 earnings announcement on 2026-03-09, the stock price moved by 0% on the day of the release. Over the subsequent five days, it saw a 0% change. Historically, RXRX's stock price tends to shift by an average of 6.2% in the 10 days leading up to earnings and -3.74% in the 10 days following, providing insight into potential market.

For 2026/Q1, analysts estimate RXRX's annual revenue to reach 16.28M, while the EPS is projected at -0.32. These estimates reflect recent revisions, with revenue estimates revised downward by -2.04% and EPS estimates unchanged by 0% over the past three months, indicating analyst expectation in the company's performance.

The correlation between RXRX's stock price and earnings forecast revisions shows that positive revisions in revenue or EPS often strengthen the stock's fundamentals. Over the past three months, revenue estimates for FY2025 were revised downward by -2.04%, while EPS estimates moved unchanged by 0%. This trend suggests that price dips could present buying opportunities for investors.

Based on historical trends, RXRX's stock price typically moves by 6.2% in the 10 days before its earnings and -3.74% in the 10 days after. For the upcoming 2026/Q1 earnings, analysts expect an EPS of -0.32 and revenue of 16.28M.

The earnings call indicates strong financial health with a cash runway extended to 2028 and reduced operating expenses. The company's partnerships, particularly with Sanofi and Roche/Genentech, are progressing well, and their AI-driven platform shows promising efficiency improvements. Despite some regulatory and strategic execution risks, the overall sentiment is positive, supported by optimistic guidance and significant partnership inflows. Given the company's small-cap status, these factors are likely to result in a positive stock price movement over the next two weeks.